Erlotinib-induced trichomegaly in a male patient with pancreatic cancer

Cutaneous and Ocular Toxicology

Volumn 29, Issue 1, 2010, Pages 62-66

  Saif, Muhammad Wasif ^a   Gnanaraj, Joseph ^b  

^a YALE CANCER CENTER   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

EGFR inhibitors; Erlotinib; Eyes; Male patient; Pancreatic cancer; Trichomegaly

Indexed keywords

ERLOTINIB; GEMCITABINE;

ACNE; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; DRUG TOLERABILITY; ERYTHEMA; EYELASH; FATIGUE; HAIR DISEASE; HUMAN; LIVER METASTASIS; LUNG CANCER; MALE; PANCREAS CANCER; PROGNOSIS; SIDE EFFECT; SINGLE DRUG DOSE; TREATMENT DURATION; TRICHOMEGALY;

AGED; ANTINEOPLASTIC AGENTS; EYEBROWS; EYELASHES; FEMALE; HUMANS; HYPERTRICHOSIS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 77149145169     PISSN: 15569527     EISSN: 15569535     Source Type: Journal    
DOI: 10.3109/15569520903440058     Document Type: Article

References (32)

1. Nanney LB, Magid M, Stoscheck CM, King LE Jr. Comparison of epidermal growth factor binding and receptor distribution in normal human epidermis and epidermal appendages. J Invest Dermatol 1984;83:385-393
2. Busam KJ, Capodieci P, Motzer R, Kiehn T, Phelan D, Halpern AC. Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatology 2001;144:1169-1176
3. Baselga J. The EGFR as a target for anticancer therapy-focus on cetuximab.Eur J Cancer 2001;37(suppl 4):S16-S22.
4. Shepherd FA, Pereira J, Ciuleanu TE, Tan EH, Hirsh V, Thongprasert S, et al. A randomized placebo controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of first line or second line chemotherapy: a National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial. J Clin Oncol 2004;22(14S):7022 (Abstract).
5. Baselga J, Rischin D, Ranson M, Calvert H, Raymond E, Kieback DG, et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 2002;20:4292-4302 (Pubitemid 35266289)
6. Santmyire-Rosenberger BR, Albert M. Acquired trichomegaly with topiramate. J Am Acad Dermatol 2005;53:362-363
7. Carser JE, Summers YJ. Trichomegaly of the eyelashes after treatment with erlotinib in non-small-cell lung cancer. J Thorac Oncol 2006;1:1040-1041
8. Lane K, Goldstein SM. Erlotinib-associated trichomegaly. Ophthal Plast Reconstr Surg 2007;23:65-66
9. Oliver GL, McFarlane DC. Congenital trichomegaly with associated pigmentary degeneration of the retina, dwarfism, and mental retardation. Arch Ophthalmol 1965;74:169-171
10. Ziakas NG, Jogiya A, Michaelides M. A case of familial trichomegaly in association with oculocutaneous albinism type 1. Eye (Lond). 2004 Aug;18(8):863-864
11. Harrison DA, Mullaney PB. Familial trichomegaly. Arch Ophthalmol 1997;115:1602-1603
12. Sharma RC, Mahajan VK, Sharma NL, Sharma A. Trichomegaly of the eyelashes in dermatomyositis. Dermatology 2002;205:305.
13. Santiago M, Travassos AC, Rocha MC, Souza S. Hypertrichosis in systemic lupus erythematosus (SLE). Clin Rheumatol 2000;19:245-246
14. Slee PH, Van der Waal RI, Schagen van Leeuwen JH, Tupker RA, Timmer R, Seldenrijk CA, et al. Paraneoplastic hypertrichosis lanuginosa acquisita: uncommon or overlooked? Br J Dermatol 2007;157:1087-1092
15. Vulink AJ, Ten Bokkel HD. Acquired hypertrichosis lanuginosa: a rare cutaneous paraneoplastic syndrome. J Clin Oncol 2007;25:1625-1626
16. Kaplan MH, Sadick NS, Talmor M. Acquired trichomegaly of the eyelashes: a cutaneous marker of acquired immunodeficiency syndrome. J Am Acad Dermatol 1991;25:801-804
17. Bouche O, Brixi-Benmansour H, Bertin A, Perceau G, Lagarde S. Trichomegaly of the eyelashes following treatment with cetuximab. Ann Oncol 2005;16:1711-1712
18. Shah NT, Kris MG, Pao W, Tyson LB, Pizzo BM, Heinemann MH, et al. Practical management of patients with non-small-cell lung cancer treated with gefitinib. J Clin Oncol 2005;23:165-174
19. Klutman NE, Hinthorn DR. Excessive growth of eyelashes in a patient with AIDS being treated with zidovudine. N Engl J Med 1991;324:1896.
20. Elgin U, Batman A, Berker N, Ilhan B. The comparison of eyelash lengthening effect of latanoprost therapy in adults and children. Eur J Ophthalmol 2006;16:247-250
21. Centofanti M, Oddone F, Chimenti S, Tanga L, Citarella L, Manni G. Prevention of dermatologic side effects ofbimatoprost 0.03% topical therapy. Am J Ophthalmol 2006;142:1059-1060
22. Weaver DT, Bartley GB. Cyclosporine-induced trichomegaly. Am J Ophthalmol 1990;109:239.
23. Ward KM, Barnett C, Fox LP, Grossman ME. Eyelash trichomegaly associated with systemic tacrolimus. Arch Dermatol 2006;142:248.
24. Hernandez-Nunez A, Fernandez-Herrera J, Buceta LR, Garcia-Diez A. Trichomegaly following treatment with interferon alpha-2b. Lancet 2002;359:1107.
25. Nanney LB, Stoscheck CM, King LE Jr, Underwood RA, Holbrook KA. Immunolocalization of epidermal growth factor receptors in normal developing human skin. J Invest Dermatol. 1990;94:742-748
26. Fox LP. Pathology and management of dermatologic toxicities associated with anti-EGFR therapy. Oncology (Williston Park) 2006;20(5 suppl 2):26-34.
27. Peus D, Hamacher L, Pittelkow MR. EGF-receptor tyrosine kinase inhibition induces keratinocyte growth arrest and terminal differentiation. J Invest Dermatol. 1997;109:751-756
28. Burtness B, Anadkat M, Basti S, Hughes M, Lacouture ME, McClure JS, et al. MDNCCN task force report: management of dermatologic and other toxicities associated with EGFR inhibition in patients with cancer.J Natl Compr Cancer Network 2009;7(suppl 1). Available at: http://www.nccn.org/ JNCCN/PDF/2009-Derm- Tox-TF.pdf (accessed November 2009).
29. Alexandrescu DT, Kauffman CL, Dasanu CA. Persistent hair growth during treatment with the EGFR inhibitor erlotinib. Dermatol Online J 2009;15(3):4.
30. Zhang G, Basti S, Jampol LM. Acquired trichomegaly and symptomatic external ocular changes in patients receiving epidermal growth factor receptor inhibitors: case reports and a review of literature. Cornea 2007;26:858-860
31. Braiteh F, Kurzrock R, Johnson FM. Trichomegaly of the eyelashes after lung cancer treatment with the epidermal growth factor receptor inhibitor erlotinib. J Clin Oncol 2008;26:3460-3462
32. Sasmaz S, Arican O. Comparison of azelaic acid and anthralin for the therapy of patchy alopecia areata: a pilot study. Am J Clin Dermatol 2005;6:403-406